Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency
Open Access
- 20 December 2019
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (2) , 277-288
Abstract
Background: Inducible T cell co-stimulator (ICOS) deficiency has been categorized as a combined immunodeficiency often complicated by enteropathies, autoimmunity, lymphoproliferation, and malignancy. We report seven new patients and four novelICOSmutations resulting in a common variable immunodeficiency (CVID)–like phenotype and show that dysregulated IL-12 release, reduced cytotoxic T lymphocyte–associated protein 4 (CTLA4) expression, and skewing towards a Th1-dominant phenotype are all associated with inflammatory complications in this condition.Methods: A combination of whole exome and Sanger sequencing was used to identify novel mutations. Standard clinical and immunological evaluation was performed. FACS and ELISA-based assays were used to study cytokine responses and ICOS/ICOSL/CTLA4 expression following stimulation of whole blood and PBMCs with multiple TLR ligands, anti-CD3, and PHA.Results: Four novel ICOS mutations included homozygous c.323_332del, homozygous c.451C>G, and compound heterozygous c.58+1G>A/c.356T>C. The predominant clinical phenotype was that of antibody deficiency associated with inflammatory complications in 4/7 patients. Six out of seven patients were treated with immunoglobulin replacement and one patient died from salmonella sepsis. All patients who were tested showed reduced IL-10 and IL-17 cytokine responses, normal IL-1β, IL6, and TNF release following LPS stimulation and highly elevated IL-12 production in response to combined LPS/IFNγ stimulation. This was associated with skewing of CD4+T cells towards Th1 phenotype and increased expression of ICOSL on monocytes. Lastly, reduced CTLA4 expression was found in 2 patients. One patient treated with ustekinumab for pancytopenia due to granulomatous bone marrow infiltration failed to respond to this targeted therapy.Conclusions: ICOS deficiency is associated with defective T cell activation, with simultaneously enhanced stimulation of monocytes. The latter is likely to result from a lack of ICOS/ICOSL interaction which might be necessary to provide negative feedback which limits monocytes activation.Keywords
Funding Information
- Jeffrey Modell Foundation (NA)
- Leeds Hospital Charitable Foundation (9/R21/14-07)
- NIHR Leeds Biomedical Research Centre. (NA)
This publication has 36 references indexed in Scilit:
- 14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator DeficiencyFrontiers in Immunology, 2017
- Next Generation Sequencing Data Analysis in Primary Immunodeficiency Disorders – Future DirectionsJournal of Clinical Immunology, 2016
- Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015Journal of Clinical Immunology, 2015
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesNature Medicine, 2015
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutationsNature Medicine, 2014
- ICOS deficiency in patients with common variable immunodeficiencyClinical Immunology, 2004
- Unifying concepts in CD28, ICOS and CTLA4 co-receptor signallingNature Reviews Immunology, 2003
- Renal Tubular Epithelial Expression of the Costimulatory Molecule B7RP-1 (Inducible Costimulator Ligand)Journal of the American Society of Nephrology, 2002
- Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T CellsThe Journal of Immunology, 2000
- B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFαImmunity, 1999